Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Jan 15, 2020 06:00AM Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics
Jan 13, 2020 04:47PM Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 13, 2020 08:17AM Mri Interventions, Inc. (MRIC) Obtains $17.5 Million Strategic Investment from PTC Therapeutics (PTCT) and Petrichor Healthcare Capital Management
Jan 13, 2020 08:05AM MRI Interventions, Inc. Obtains a $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management
Jan 13, 2020 08:00AM Allergan and Avitide Expand Partnership to Develop Custom Affinity Chromatography Technologies
Jan 6, 2020 08:32AM Sonendo® Announces Growth Investment from EW Healthcare Partners
Dec 26, 2019 04:02PM Form SC 13D/A Nabriva Therapeutics Filed by: ORBIMED ADVISORS LLC
Dec 19, 2019 04:39PM Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 13, 2019 04:32PM Form SC 13G/A Principia Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
Dec 12, 2019 05:20PM Form 4 Tricida, Inc. For: Dec 11 Filed by: ORBIMED ADVISORS LLC
Dec 12, 2019 05:20PM Form SC 13D/A Tricida, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 11, 2019 08:00AM PMV Pharma Appoints Leila Alland, M.D., as Chief Medical Officer
Dec 9, 2019 08:00AM Gemini Therapeutics and Avitide Enter Into Exclusive License Agreement
Dec 6, 2019 04:47PM Form SC 13D/A Nabriva Therapeutics Filed by: ORBIMED ADVISORS LLC
Dec 3, 2019 07:00AM Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth
Nov 27, 2019 06:06AM Form SC 13D Sierra Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 26, 2019 07:00AM Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors
Nov 25, 2019 04:34PM Form SC 13D TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 25, 2019 04:32PM Form SC 13D 89bio, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 19, 2019 05:10PM Form SC 13D/A NextCure, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 15, 2019 08:40AM Sinovac Reports Unaudited Third Quarter 2019 Financial Results
Nov 14, 2019 04:12PM Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
Nov 13, 2019 08:48PM Form 4 TELA Bio, Inc. For: Nov 08 Filed by: ORBIMED ADVISORS LLC
Nov 13, 2019 07:01PM Form 4 89bio, Inc. For: Nov 11 Filed by: OrbiMed Advisors Israel II Ltd
Nov 13, 2019 12:58PM Form SC 13D/A SELECTA BIOSCIENCES INC Filed by: ORBIMED ADVISORS LLC
Nov 13, 2019 08:02AM PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
Nov 13, 2019 08:00AM RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline
Nov 12, 2019 02:32PM Form SC 13G ESSA Pharma Inc. Filed by: ORBIMED ADVISORS LLC
Nov 8, 2019 07:16PM Form 3 89bio, Inc. For: Nov 08 Filed by: OrbiMed Advisors Israel II Ltd
Nov 7, 2019 09:03PM Form 3 TELA Bio, Inc. For: Nov 07 Filed by: ORBIMED ADVISORS LLC
Nov 6, 2019 04:05PM Natera Reports Third Quarter 2019 Financial Results
Oct 22, 2019 08:38AM PlacementTracker Publishes Q3 2019 PIPE and Private Placement Markets League Tables
Oct 7, 2019 06:00AM Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases
Sep 30, 2019 07:00AM Poul Sorensen Receives the 2019 Bloom Burton Award
Sep 25, 2019 04:42PM Form SC 13D SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC
Sep 18, 2019 04:17PM Form SC 13D BELLUS Health Inc. Filed by: ORBIMED ADVISORS LLC
Sep 17, 2019 09:00AM Edgewise Therapeutics Closes $50 Million Series B Financing
Sep 12, 2019 04:43PM Form 3 SpringWorks Therapeutics For: Sep 12 Filed by: ORBIMED ADVISORS LLC
Sep 9, 2019 02:05PM Form SC 13D/A AVEDRO INC Filed by: ORBIMED ADVISORS LLC
Sep 9, 2019 09:09AM BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United States
Aug 20, 2019 09:00AM Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs
Aug 20, 2019 09:00AM Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program
Aug 20, 2019 09:00AM Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program
Aug 15, 2019 04:05PM Sinovac Reports Unaudited Second Quarter 2019 Financial Results
Aug 14, 2019 04:58PM Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
Aug 14, 2019 04:38PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Aug 13, 2019 05:12PM Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 12, 2019 05:16PM Form SC 13D/A SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
Aug 12, 2019 06:02AM Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 8, 2019 04:59PM Form 4 Corvus Pharmaceuticals, For: Aug 06 Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed